Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Operating Expenses (2020 - 2025)

Cytek Biosciences' Operating Expenses history spans 6 years, with the latest figure at $38.5 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 25.48% year-over-year to $38.5 million; the TTM value through Dec 2025 reached $144.8 million, up 10.04%, while the annual FY2025 figure was $144.8 million, 10.04% up from the prior year.
  • Operating Expenses reached $38.5 million in Q4 2025 per CTKB's latest filing, up from $36.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $38.5 million in Q4 2025 to a low of $13.4 million in Q1 2021.
  • Average Operating Expenses over 5 years is $29.3 million, with a median of $33.2 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 106.4% in 2021, then fell 8.92% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $22.3 million in 2021, then skyrocketed by 31.23% to $29.3 million in 2022, then rose by 13.3% to $33.2 million in 2023, then decreased by 7.59% to $30.7 million in 2024, then grew by 25.48% to $38.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Operating Expenses are $38.5 million (Q4 2025), $36.7 million (Q3 2025), and $34.5 million (Q2 2025).